Table 2 Representative trials using combination of radiotherapy and immunotherapy
From: Radiotherapy combined with immunotherapy: the dawn of cancer treatment
ClinicalTrials.gov identifier | Trial Phase | Condition or disease | Sequence | RT | IO | Results | Sponsors | Estimated/actual study completion date |
|---|---|---|---|---|---|---|---|---|
NCT02474186 | Phase 1 Phase 2 | Various | Concurrent | 35 Gy in 10 fractions | GM-CSF | Abscopal responses in 27.6% of patients | NYU Langone Health | July 2015 |
NCT02125461 | Phase 3 | NSCLC | RT, IO | 54 to 66 Gy | Durvalumab | Durable PFS and sustained OS benefit with durvalumab after chemoradiotherapy | AstraZeneca | December 30, 2022 |
NCT02608385 | Phase 1 | Solid tumors | SBRT, IO | SBRT dosing varied by site and ranged from 30 to 50 Gy in three to five fractions | Pembrolizumab | Well tolerated with acceptable toxicity | University of Chicago | July 2022 |
NCT02221739 | Phase 1 Phase 2 | NSCLC | Concurrent | 6 Gy x5, later changed to 9.5 Gy x3 | Ipilimumab | Objective responses were observed in 18%, and 31% had disease control | NYU Langone Health | October 27, 2015 |
NCT02434081 | Phase 2 | NSCLC | Concurrent | 66 Gy in 33 fractions | Nivolumab | The addition of nivolumab to concurrent CRT is safe and tolerable | European Thoracic Oncology Platform | March 31, 2020 |
NCT02492568 | Phase 2 | NSCLC | RT, IO | SBRT 3 doses of 8 Gy | Pembrolizumab | Well tolerated and a doubling of ORR | The Netherlands Cancer Institute | June 2018 |
NCT02444741 | Phase 1 Phase 2 | NSCLC | Concurrent | Various | Pembrolizumab | Safe and more beneficial for patients with low PD-L1 expression | M.D. Anderson Cancer Center | September 17, 2022 |
NCT02343952 | Phase 2 | Carcinoma, NSCLC | RT, IO | 59.4 to 66.6 Gy | Pembrolizumab | PFS and OS improvement with consolidation pembrolizumab | Nasser Hanna, M.D. | September 2022 |
NCT03631784 | Phase 2 | NSCLC | Concurrent | 60 Gy in 30 daily fractions | Pembrolizumab | Promising antitumor activity and manageable safety | Merck Sharp & Dohme Corp. | May 15, 2023 |
Ongoing or completed clinical trials using combination of radiotherapy and immunotherapy for NSCLC | ||||||||
ClinicalTrials.gov identifier | Trial Phase | Condition or disease | Sequence | RT | IO | Status | Sponsors | Estimated/Actual study completion date |
PD-1 inhibitor | ||||||||
NCT03035890 | Not Applicable | Metastatic NSCLC | Concurrent | Hypo-fractionated Radiation | Immuno-Therapeutic Agent (Nivolumab/ pembrolizumab/ atezolizumab) | Active, not recruiting | West Virginia University | June 30, 2023 |
NCT05111197 | Phase 3 | Locally advanced or metastatic NSCLC | IO, RT | SBRT | Anti-PD-1 or anti-PD-L1 immunotherapy | Not yet recruiting | Institut Cancerologie de l’Ouest | December 2024 |
NCT03523702 | Phase 2 | Locally Advanced NSCLC | Concurrent | Selective personalized radiotherapy | Pembrolizumab | Recruiting | Albert Einstein College of Medicine | September 2022 |
NCT03383302 | Phase 1 Phase 2 | NSCLC Stage II and Stage I | RT, IO | SBRT | Nivolumab | Recruiting | Royal Marsden NHS Foundation Trust | January 2022 |
NCT03825510 | Not Applicable | Metastatic NSCLC | RT, IO | SBRT | Nivolumab/ pembrolizumab | Recruiting | Crozer-Keystone Health System | August 28, 2021 |
NCT04577638 | Phase 2 | NSCLC Stage III | Concurrent | Intensity Modulated Radiotherapy | Nivolumab | Recruiting | Center Eugene Marquis | February 1, 2024 |
NCT03168464 | Phase 1 Phase 2 | NSCLC Metastatic | Concurrent | 6 Gy x 5 fractions | Ipilimumab/ nivolumab | Recruiting | Weill Medical College of Cornell University | December 30, 2022 |
NCT03867175 | Phase 3 | Stage IV NSCLC | Concurrent | SBRT | Pembrolizumab | Recruiting | Wake Forest University Health Sciences | December 31, 2027 |
NCT03110978 | Phase 2 | Stage I-IIA or Recurrent NSCLC | Concurrent | SBRT | Nivolumab | Recruiting | M.D. Anderson Cancer Center | June 30, 2022 |
NCT03812549 | Phase 1 | Stage IV NSCLC | RT, IO | SBRT/LDRT | Sintilimab | Recruiting | Sichuan University | December 31, 2022 |
NCT03313804 | Phase 2 | NSCLC, Squamous Cell Carcinoma of the Head and Neck | IO, RT | SBRT | Nivolumab/ pembrolizumab/ atezolizumab | Recruiting | John L. Villano, MD, PhD | June 30, 2028 |
NCT04929041 | Phase 2 Phase 3 | Stage IV NSCLC | Concurrent | SBRT | Ipilimumab/nivolumab/ pembrolizumab | Recruiting | National Cancer Institute (NCI) | December 31, 2027 |
NCT03774732 | Phase 3 | NSCLC Metastatic | Concurrent | SBRT | Pembrolizumab | Recruiting | UNICANCER | September 21, 2024 |
NCT05229614 | Phase 2 | NSCLC, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma | IO, RT | Carbon ion therapy | Pembrolizumab | Not yet recruiting | CNAO National Center of Oncological Hadrontherapy | August 2026 |
NCT03705806 | Stage IV NSCLC | IO, RT | 30 Gy in 10 fractions | PD-1 inhibitor | Recruiting | University Health Network, Toronto | September 15, 2022 | |
NCT03224871 | Early Phase 1 | Metastatic NSCLC | Concurrent | Hypo-fractionated Radiotherapy | Intralesional IL-2, nivolumab, pembrolizumab | Completed | University of California, Davis | January 10, 2020 |
NCT05265650 | Phase 1 Phase 2 | Metastatic NSCLC | Concurrent | SBRT | Nivolumab | Not yet recruiting | Clinica Universidad de Navarra, Universidad de Navarra | June 2024 |
NCT04513301 | Phase 2 | Recurrent or IV NSCLC after failure of platinum-based chemotherapy | Concurrent | 50-60 Gy/25-30 f | Sintilimab | Recruiting | Shanghai Cancer Hospital, China | December 1, 2022 |
NCT05222087 | Phase 1 | Metastatic NSCLC | RT, IO | SBRT | Pembrolizumab | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | April 2024 |
NCT02444741 | Phase 1 Phase 2 | Stage IV NSCLC | Concurrent | SBRT | Pembrolizumab | Active, not recruiting | M.D. Anderson Cancer Center | September 17, 2022 |
NCT03217071 | Phase 2 | Stage I-IIIA NSCLC | IO, RT | SBRT | Pembrolizumab | Active, not recruiting | Sue Yom | February 28, 2022 |
NCT02492568 | Phase 2 | Advanced NSCLC | RT, IO | SBRT 3 doses of 8 Gy | Pembrolizumab | Completed | The Netherlands Cancer Institute | June 2018 |
NCT04892849 | Not Applicable | HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Skin, Small Cell Bronchial Carcinomas | IO, RT | RT | PD-1/PD-L1 inhibitor | Recruiting | University of Erlangen-Nürnberg Medical School | December 31, 2027 |
NCT03223155 | Phase 1 | Stage IV NSCLC | Concurrent or sequential | SBRT | Ipilimumab/ nivolumab | Recruiting | University of Chicago | December 2024 |
NCT04013542 | Phase 1 | Stage II–III NSCLC | Concurrent | RT | Ipilimumab and nivolumab | Recruiting | M.D. Anderson Cancer Center | February 1, 2022 |
NCT04902040 | Phase 1 Phase 2 | Advanced Bladder Carcinoma, Advanced NSCLC, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma | RT, IO | RT | Atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab | Recruiting | M.D. Anderson Cancer Center | June 1, 2025 |
NCT04271384 | Phase 2 | Stage 1 NSCLC | Concurrent | SBRT | Nivolumab | Recruiting | Hospital Israelita Albert Einstein | June 29, 2023 |
NCT04291092 | Phase 2 | NSCLC Stage IV Brain Metastases | WBRT | Camrelizumab | Recruiting | Zhejiang Cancer Hospital | June 30, 2023 | |
NCT04167657 | Phase 2 | Advanced NSCLC | RT, IO | RT | Sintilimab | Recruiting | Peking Union Medical College Hospital | April 15, 2023 |
NCT02818920 | Phase 2 | Stage IB, II or IIIA NSCLC | IO, RT | RT | Pembrolizumab | Active, not recruiting | Neal Ready | March 2026 |
NCT03589339 | Phase 1 | Advanced cancers (Metastatic NSCLC) | IO, RT | SBRT | Nivolumab/ pembrolizumab | Recruiting | Nanobiotix | March 30, 2023 |
NCT04977453 | Phase 1 Phase 2 | NSCLC, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma | SBRT | Pembrolizumab | Recruiting | GI Innovation, Inc. | December 2025 | |
PD-L1 inhibitor | ||||||||
NCT03965468 | Phase 2 | NSCLC Stage IV Oligometastasis | Concurrent | SBRT | Durvalumab | Recruiting | European Thoracic Oncology Platform | December 2021 |
NCT03035890 | Not Applicable | Metastatic NSCLC | Concurrent | Hypo-fractionated Radiation | Immuno-Therapeutic Agent (Nivolumab/ pembrolizumab/ atezolizumab) | Active, not recruiting | West Virginia University | June 30, 2023 |
NCT05000710 | Phase 2 | Metastatic or Locally Advanced NSCLC | Concurrent | 11 fractions of 3 Gy | Durvalumab/ tremelimumab | Recruiting | Sheba Medical Center | December 2026 |
NCT05111197 | Phase 3 | Locally advanced or metastatic NSCLC | IO, RT | SBRT | Anti-PD-1 or anti-PD-L1 immunotherapy | Not yet recruiting | Institut Cancerologie de l’Ouest | December 2024 |
NCT04765709 | Phase 2 | Large volume stage III NSCLC | Concurrent | RT | Durvalumab | Not yet recruiting | Mario Negri Institute for Pharmacological Research | June 2026 |
NCT04549428 | Phase 2 | NSCLC Stage IV | Concurrent | a single fraction of 8 Gy | Atezolizumab | Recruiting | Oncology Institute of Southern Switzerland | July 31, 2022 |
NCT04245514 | Phase 2 | NSCLC | Concurrent | 20 × 2 Gy (weekdaily, 4 weeks) 5 × 5 Gy (weekdaily, 1 week) 3 × 8 Gy (on alternate days, 1 week) | Durvalumab | Recruiting | Swiss Group for Clinical Cancer Research | March 2025 |
NCT05267392 | Phase 1 Phase 2 | Early stage or locally advanced, unresectable NSCLC | IO, RT | Standard of care RT/RCT | Durvalumab | Recruiting | Instituto Portugues de Oncologia, Francisco Gentil, Porto | January 2024 |
NCT05128630 | Phase 2 | NSCLC, Stage III | Concurrent | reduced-dose hypo-fractionated thoracic RT | Durvalumab | Recruiting | IRCCS Policlinico S. Matteo | November 28, 2025 |
NCT04989283 | Phase 2 | Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma | Concurrent | External Beam Radiation Therapy | Atezolizumab | Recruiting | National Cancer Institute (NCI) | May 10, 2031 |
NCT03313804 | Phase 2 | NSCLC, Squamous Cell Carcinoma of the Head and Neck | IO, RT | SBRT | Nivolumab/ pembrolizumab/ atezolizumab | Recruiting | John L. Villano, MD, PhD | June 30, 2028 |
NCT03275597 | Phase 1 | NSCLC Stage IV | IO, RT | SBRT | Durvalumab + tremelimumab | Active, not recruiting | University of Wisconsin, Madison | July 2025 |
NCT04372927 | Phase 2 | Locally Advanced NSCLC | Concurrent | Adaptive mediastinal radiation | Durvalumab | Recruiting | University of Washington | November 30, 2026 |
NCT03916419 | Phase 2 | Stage IIB, IIIA, and Select IIIB and IIIC NSCLC | Concurrent | MR-Linear Accelerator-Radiation | Durvalumab | Recruiting | Washington University School of Medicine | December 31, 2024 |
NCT04230408 | Phase 2 | Stage III NSCLC | IO, RT, IO | 54 to 66 Gy | Durvalumab | Recruiting | Latin American Cooperative Oncology Group | May 2024 |
NCT04992780 | Phase 2 | NSCLC | RT, IO | Hypo-Fractionation 62.5 Gy in 25 fractions of 2.5 Gy/fraction; Standard-Fractionation 60 Gy in 30 fractions of 2 Gy/fraction | Durvalumab | Not yet recruiting | University of Kansas Medical Center | November 2023 |
NCT03446547 | Phase 2 | Stage I NSCLC | RT, IO | SBRT | Durvalumab | Recruiting | Vastra Gotaland Region | July 2023 |
NCT05034055 | Phase 2 | Metastatic NSCLC | RT, IO | SBRT | Atezolizumab/tiragolumab | Not yet recruiting | Yonsei University | December 2023 |
NCT05157542 | Phase 1 | Stage III NSCLC | Concurrent | Low dose radiation therapy | Durvalumab | Recruiting | Juan LI, MD | June 10, 2023 |
NCT03391869 | Phase 3 | Stage IV NSCLC | IO, RT | Local consolidation therapy | Nivolumab and ipilimumab | Recruiting | M.D. Anderson Cancer Center | December 31, 2022 |
NCT03818776 | Early Phase 1 | Unresectable NSCLC | Concurrent | Proton beam therapy RT | Durvalumab | Recruiting | Case Comprehensive Cancer Center | November 1, 2023 |
NCT03801902 | Phase 1 | Locally advanced NSCLC | IO, RT | Hypofractionated Radiation Therapy/Fractionated Stereotactic Radiation Therapy | Durvalumab | Active, not recruiting | National Cancer Institute (NCI) | January 5, 2023 |
NCT02463994 | Early Phase 1 | Metastatic NSCLC | RT, IO | Hypo-fractionated Image-guided Radiotherapy | PD-L1 antibody | Completed | University of Michigan Rogel Cancer Center | November 7, 2018 |
NCT02888743 | Phase 2 | Metastatic Colorectal or NSCLC | IO, RT | high dose radiation therapy/low dose radiation therapy | Tremelimumab and durvalumab | Active, not recruiting | National Cancer Institute (NCI) | December 31, 2022 |
NCT04944173 | Phase 2 | Stage I NSCLC | Concurrent | SBRT | Durvalumab | Not yet recruiting | University of British Columbia | December 2024 |
NCT04310020 | Phase 2 | Stage II or III NSCLC | IO, RT | Hypo-fractionated Radiation Therapy | Atezolizumab | Recruiting | National Cancer Institute (NCI) | March 15, 2022 |
NCT04081688 | Phase 1 | Refractory NSCLC Stage IV | SBRT | Atezolizumab/ varlilumab | Recruiting | Rutgers, The State University of New Jersey | June 30, 2023 | |
NCT04889066 | Phase 2 | Brain metastases NSCLC | Concurrent | Personalized ultra-fractionated stereotactic adaptive radiotherapy or Fractionated Stereotactic Radiotherapy | Durvalumab | Not yet recruiting | University of Texas Southwestern Medical Center | January 2025 |
NCT04892849 | Not Applicable | HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Skin, Small Cell Bronchial Carcinomas | IO, RT | RT | PD-1/PD-L1 inhibitor | Recruiting | University of Erlangen-Nürnberg Medical School | December 31, 2027 |
NCT04202809 | Phase 2 | Resectable Stage III NSCLC | Concurrent | RT | Durvalumab | Recruiting | University Hospital, Essen | April 2024 |
NCT03237377 | Phase 2 | Stage III Resectable NSCLC | Concurrent | Thoracic radiation: 45 Gy in 25 fractions | Durvalumab or durvalumab plus tremelimumab | Active, not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | September 2022 |
NCT04214262 | Phase 3 | Stage I-IIA NSCLC | Induction/Consolidation Atezoli-zumab + SBRT | SBRT | Atezolizumab | Recruiting | National Cancer Institute (NCI) | May 1, 2028 |
NCT03871153 | Phase 2 | Stage III NSCLC | Concurrent | 45-61.2 Gy/25-30 f | Durvalumab | Active, not recruiting | Greg Durm, MD | April 2023 |
NCT03141359 | Phase 2 | Locally advanced NSCLC | IO, RT | IMRT/SBRT | Durvalumab | Recruiting | Atrium Health | May 2026 |
NCT04902040 | Phase 1 Phase 2 | Advanced Bladder Carcinoma, Advanced NSCLC, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma | RT, IO | RT | Atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab | Recruiting | M.D. Anderson Cancer Center | June 1, 2025 |
NCT05198830 | Phase 2 | Stage III Non-Squamous NSCLC | RT, IO | RT | Durvalumab | Not yet recruiting | National Cancer Institute (NCI) | May 1, 2024 |
NCT04786093 | Phase 2 | Advanced NSCLC | Concurrent | SBRT/Personalized Ultra-fractionated Stereotactic Radiotherapy | Durvalumab | Recruiting | University of Texas Southwestern Medical Center | May 2027 |
NCT04364776 | Not Applicable | Stage III Unresectable NSCLC | IO, RT | RT | Durvalumab | Recruiting | IRCCS Policlinico S. Matteo | April 15, 2024 |
NCT04892953 | Phase 2 | Stage III NSCLC | RT, IO | RT | Durvalumab | Not yet recruiting | M.D. Anderson Cancer Center | September 30, 2022 |
NCT02492867 | Not Applicable | Locally Advanced NSCLC | RT, IO | Response-driven Adaptive Radiation Therapy | Durvalumab | Active, not recruiting | University of Michigan Rogel Cancer Center | November 2024 |
NCT04238169 | Phase 2 | Stage IV NSCLC | Concurrent | SBRT | Toripalimab | Recruiting | Xinqiao Hospital of Chongqing | December 31, 2023 |
NCT04597671 | Phase 3 | Stage III NSCLC | Concurrent | Low-dose prophylactic cranial irradiation | Durvalumab | Recruiting | Association NVALT Studies | December 2032 |
NCT03337698 | Phase 1 Phase 2 | Metastatic NSCLC | Concurrent | RT | Atezolizumab | Recruiting | Hoffmann-La Roche | August 1, 2025 |
NCT04092283 | Phase 3 | Unresectable Stage III NSCLC | IO, RT, IO | RT | Durvalumab | Recruiting | National Cancer Institute (NCI) | October 31, 2028 |
NCT05259319 | Phase 1 | Metastatic NSCLC, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer | Concurrent or sequential | SBRT | Atezolizumab and tiragolumab | Not yet recruiting | Centre Georges Francois Leclerc | February 28, 2030 |
NCT03915678 | Phase 2 | Advanced solid tumors | Concurrent | SBRT | Atezolizumab | Recruiting | Institut Bergonié | March 2025 |
NCT03509012 | Phase 1 | Squamous Cell of Head and Neck Carcinoma, NSCLC | Concurrent | RT | Durvalumab/ tremelimumab | Active, not recruiting | AstraZeneca | December 29, 2023 |
CTLA-4 | ||||||||
NCT03168464 | Phase 1 Phase 2 | NSCLC Metastatic | Concurrent | 6 Gy x 5 fractions | Ipilimumab/ Nivolumab | Recruiting | Weill Medical College of Cornell University | December 30, 2022 |
NCT04929041 | Phase 2 Phase 3 | Stage IV NSCLC | Concurrent | SBRT | Ipilimumab/ Nivolumab/ Pembrolizumab | Recruiting | National Cancer Institute (NCI) | December 31, 2027 |
NCT03275597 | Phase 1 | NSCLC Stage IV | IO, RT | SBRT | Durvalumab and tremelimumab | Active, not recruiting | University of Wisconsin, Madison | July 2025 |
NCT03391869 | Phase 3 | Stage IV NSCLC | IO, RT | Local consolidation therapy | Nivolumab and ipilimumab | Recruiting | M.D. Anderson Cancer Center | December 31, 2022 |
NCT02888743 | Phase 2 | Metastatic Colorectal or NSCLC | IO, RT | high dose radiation therapy/low dose radiation therapy | Tremelimumab and durvalumab | Active, not recruiting | National Cancer Institute (NCI) | December 31, 2022 |
NCT03223155 | Phase 1 | Stage IV NSCLC | Concurrent or sequential | SBRT | Ipilimumab/Nivolumab | Recruiting | University of Chicago | December 2024 |
NCT03237377 | Phase 2 | Stage III Resectable NSCLC | Concurrent | Thoracic radiation: 45 Gy in 25 fractions | Durvalumab or durvalumab plus tremelimumab | Active, not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | September 2022 |
NCT04013542 | Phase 1 | Stage II–III NSCLC | Concurrent | RT | Ipilimumab and nivolumab | Recruiting | M.D. Anderson Cancer Center | February 1, 2022 |
NCT02221739 | Phase 1 Phase 2 | Metastatic NSCLC | Concurrent | IMRT or 3-D CRT | Ipilimumab | Completed | NYU Langone Health | October 27, 2015 |
NCT03509012 | Phase 1 | Squamous Cell of Head and Neck Carcinoma, NSCLC | Concurrent | RT | Durvalumab/ tremelimumab | Active, not recruiting | AstraZeneca | December 29, 2023 |
TIGIT inhibitor | ||||||||
NCT05034055 | Phase 2 | Metastatic NSCLC | RT, IO | SBRT | Atezolizumab/tiragolumab | Not yet recruiting | Yonsei University | December 2023 |
NCT05259319 | Phase 1 | Metastatic NSCLC, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer | Concurrent or sequential | SBRT | Atezolizumab and tiragolumab | Not yet recruiting | Centre Georges Francois Leclerc | February 28, 2030 |
Cytikines | ||||||||
NCT03705403 | Phase 2 | NSCLC Stage IV Metastatic Disease | Concurrent | SBRT | L19-IL2 | Recruiting | Maastricht University | December 1, 2023 |
NCT03224871 | Early Phase 1 | Metastatic NSCLC | Concurrent | Hypo-fractionated Radiotherapy | Intralesional IL-2, nivolumab, pembrolizumab | Completed | University of California, Davis | January 10, 2020 |
Vaccines | ||||||||
NCT00006470 | Phase 2 | NSCLC | IO, RT | RT | Monoclonal antibody 11D10 anti-idiotype vaccine or monoclonal antibody 3H1 anti-idiotype vaccine | Completed | Radiation Therapy Oncology Group | December 2004 |
NCT00828009 | Phase 2 | Unresectable Stage IIIA and IIIB Non-Squamous NSCLC | RT, IO | RT | Tecemotide | Completed | ECOG-ACRIN Cancer Research Group | May 22, 2019 |
Others | ||||||||
NCT05269485 | Phase 1 Phase 2 | Stage III NSCLC | High-dose fractionated radiotherapy: 60–68 Gy/15-17f; low-dose fractionated radiotherapy: 48 Gy/15-12f | IT | Recruiting | Anhui Provincial Hospital | June 1, 2023 | |
NCT04654520 | Not Applicable | Stage IV NSCLC | Concurrent | IMRT | IT | Not yet recruiting | Guizhou Medical University | May 31, 2022 |
NCT04650490 | Phase 2 | Brain Metastases NSCLC | IO, RT or RT, IO | SBRT | IT | Not yet recruiting | Duke University | March 2025 |
NCT03827577 | Phase 3 | Oligometastatic NSCLC | RT, IO | SBRT | IT | Recruiting | Azienda Ospedaliera Universitaria Integrata Verona | September 2022 |
NCT02839265 | Phase 2 | Advanced NSCLC | Concurrent | SBRT | FLT3 Ligand Therapy (CDX-301) | Active, not recruiting | Albert Einstein College of Medicine | October 5, 2022 |
NCT04491084 | Phase 1 Phase 2 | Advanced NSCLC | Concurrent | SBRT | FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140) | Recruiting | Albert Einstein College of Medicine | August 31, 2023 |
NCT00879866 | Phase 1 | NSCLC Stage IIIb With Malignant Pleural Effusion or Stage IV With Disease Control | RT, IO | 5 ×4 Gy | Selectikine (EMD 521873) | Completed | Merck KGaA, Darmstadt, Germany | September 2012 |
NCT04081688 | Phase 1 | Refractory NSCLC Stage IV | SBRT | Atezolizumab/ varlilumab | Recruiting | Rutgers, The State University of New Jersey | June 30, 2023 | |
